| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Blom, Burgert
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (4/4 displayed)
- 2023Synthesis and in vitro anticancer studies of arene ruthenium(II) and arene osmium(II) complexes bearing arsine and stibine co-ligands on breast cancer cell-linescitations
- 2021Ionic Ruthenium and Iron Based Complexes Bearing Silver Containing Anions as a Potent New Class of Anticancer Agentscitations
- 2021Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agentscitations
- 2019Heterobimetallic Ru(μ-dppm)Fe and homobimetallic Ru(μ-dppm)Ru complexes as potential anti-cancer agentscitations
Places of action
| Organizations | Location | People |
|---|
article
Synthesis and in vitro anticancer studies of arene ruthenium(II) and arene osmium(II) complexes bearing arsine and stibine co-ligands on breast cancer cell-lines
Abstract
We report the synthesis and full characterisation of piano-stool triphenylstibine and triphenylarsine arene complexes of the type: [MCl2(?6-p-cymene)(EPh3)] (E = As, Sb) and [MCl(?6-arene)(EPh3)(SnCl3)] (M = Ru, Os; E = As, Sb; arene = benzene, p-cymene); Ph = C6H5) and their in vitro cytotoxic evaluation on two breast cancer cell lines: MCF-7, MDA-MB-231 and MCF-12A. The compounds were synthesized via a facile two-step reaction: first, the cleavage of the corresponding dimer [(MCl2(?6-arene))2] (M = Ru, Os; arene = benzene, p-cymene) by either: AsPh3 or:SbPh3 to yield the mononuclear dichloride complexes [MCl2(?6-arene)(EPh3)] (M = Ru, Os; E = As, Sb; arene = benzene, p-cymene) 2: (M = Os, E = Sb, arene = p-cymene), 3: (M = Os, E = As, arene = p-cymene); and the known complexes 6: (M = Ru, E = Sb, arene = p-cymene), 7: (M = Ru, E = As, arene = p-cymene), 8: (M = Ru, E = Sb, arene = benzene) and 9: (M = Ru, E = As, arene = benzene). Using these dichloride complexes as starting materials, SnCl2 was inserted into the M-Cl bond to form the chiral trichlorostannyl complexes [MCl(?6-arene)(EPh3)(SnCl3)] (M = Ru, Os; E = As, Sb; arene = benzene, p-cymene) 4: (M = Os, E = Sb, arene = p-cymene), 5: (M = Os, E = As, arene = p-cymene), 10: (M = Ru, E = Sb, arene = p-cymene), 11: (M = Ru, E = As, arene = p-cymene), 12: (M = Ru, E = Sb, arene = benzene), and 13: (M = Ru, E = As, arene = benzene) respectively. The complexes were characterized spectroscopically by means of 1H, 13C{1H} NMR, FTIR, MP, UV–Visible and ESI-MS. The single crystal X-ray diffraction analysis of complex 2 and 10 is also reported revealing the expected piano-stool geometry at the metal centre. The in vitro activity of the complexes on the MCF-7, MDA-MB-231 and the non-tumorigenic cell-line MCF-12A are reported and compared to cisplatin as a positive control. Several tin containing complexes (4, 5, 10 and 12) show remarkable activity and selectivity outperforming cisplatin on both cancer cell-lines with the ruthenium complexes being the most active overall in this series of compounds. One of the most active complexes, 10 was also subjected to ToF-SIMS and the results of this study are reported.